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Abstract: Pancreatic ductal adenocarcinoma (PDAC) carries the worst prognosis and caused one of the highest 
cancer-related mortalities. Dendritic cell (DC) vaccination is a promising cancer immunotherapy; however, the clini-
cal outcomes are often poor. The administration route of DC vaccine can significantly alter the anti-tumor immune 
response. Here we report on the cytotoxic T lymphocyte (CTL) responses induced by DC vaccination administered via 
intraperitoneal (IP) for murine PDAC, and the longitudinal assessment of tumor growth and therapeutic responses 
using magnetic resonance imaging (MRI). In this study, we established murine orthotopic Panc02 models of PDAC 
and delivered apoptotic Panc02 cell-pulsed DCs via IP injection. The migration of Panc02-pulsed DCs into spleens 
significantly increased from 6 h to 12 h after initiation of treatment (P = 0.002), and Panc02-pulsed DCs injected 
via IP induced a significantly higher level of CTL responses against Panc02 cells compared to unpulsed DCs. Tumor 
size and tumor apparent diffusion coefficient (ADC) were measured on MR images. Tumor sizes were significantly 
smaller in the treated mice than in the untreated mice (P < 0.05). The reduction of tumor ADC was less in the treated 
mice than in the untreated mice (P < 0.05), and the changes in tumor ADC showed significant negative correlation 
with the changes in tumor volume (r = -0.882, 95% confidence interval, -0.967 to -0.701, P < 0.0001). These results 
demonstrated the efficacy of DC vaccination administered via IP injection in murine PDAC, and the feasibility of ADC 
measurement as an imaging biomarker for assessment of therapeutic responses in immunotherapy.
Keywords: Pancreatic ductal carcinoma, dendritic cell, vaccination, intraperitoneal injection, magnetic resonance 
imaging
Introduction
Pancreatic ductal adenocarcinoma (PDAC) 
accounts for over 95% of all pancreatic malig-
nancies. The 5-year survival rate is approxi-
mately 7.1% and the median overall survi- 
val (OS) is 4-6 months for all patients with PDAC 
[1, 2]. Surgical resection, the only potentially 
curative treatment, is applicable in only 5% to 
25% patients; even after surgery, the 5-year 
survival rate is less than 20% [3]. Local abla-
tion and systemic chemotherapy have offered 
little benefit [4]. Thus, new approaches are 
urgently needed to treat this deadly disease 
effectively.
Recently, many immunotherapies are based on 
the vaccination of cancer patients with autolo-
gous DCs loaded with tumor antigens (DC vac-
cines) [5-7]. DCs are the main type of antigen-
presenting cells (APCs), and the aim of DC 
vaccination is to induce tumor-specific effector 
T cells that can specifically reduce the tumor 
mass and induce immunological memory to 
control tumor recurrence [8-10]. DC vaccination 
has clinically relevant mechanisms of action 
MRI monitoring DC vaccine in murine pancreatic cancer models
563 Am J Cancer Res 2019;9(3):562-573
with a great potential for the systemic treat-
ment of cancers in a clinical setting. However, 
clinical trials have demonstrated its poor thera-
peutic efficacy [11-13]. The efficacy of DC vac-
cination is strongly influenced by DC vaccine 
migration to the draining lymph nodes (LNs). It 
has been reported that the administration 
route of DC vaccine can significantly alter the 
anti-tumor immune response and immune 
memory [13, 14]. Administration routes includ-
ing subcutaneous, intradermal, intratumoral, or 
intranodal injection have been applied in both 
preclinical research and clinical trials [15, 16]. 
However, only a small number of DCs can 
migrate to LNs and lymphoid organs by subcu-
taneous or intradermal injection [17, 18]. A 
direct delivery of DCs by intratumoral injection 
or by intranodal injection could impair the effi-
cacy of DC vaccine [18, 19]. Given that a large 
number of LNs in the abdomen composes the 
most important secondary lymphoid organ and 
the fact that spleen is the largest lymphatic 
organ in the abdomen, we have very recently 
tested the migration of DCs to LNs via intraperi-
toneal (IP) injection, and the results indicated 
that IP injection could increase the amount of 
viable DC vaccines actively absorbed by LNs 
and improve outcomes. 
Magnetic resonance imaging (MRI), which can 
provide anatomic and functional information 
about tumors, has a well-established role in the 
evaluation of patients with PDAC [20]. Diffusion 
weighted MRI (DW-MRI), which reflects the dif-
fusion of water molecules within biological tis-
sues, provides microstructural information at 
the cellular level [21, 22]. The apparent diffu-
sion coefficient (ADC), which can be quantifi- 
ed from DW-MRI, decreases when water mo- 
lecule movements are hindered by any obsta-
cle; in particular, it has been proved to reduce 
in tissues with high cell density [23]. Studies on 
a variety of tumor types reported that tumor 
ADC could act as an imaging biomarker for 
early detection of cancer treatment response 
[24-27]. To the best of our knowledge, no stud-
ies have assessed DC vaccine therapeutic 
responses in PDAC using DWI.
The purpose of our study was to test the fo- 
llowing hypotheses in a murine model of PDAC: 
(a) DC vaccines administered via IP injection 
can effectively induce tumor-specific cyto- 
toxic T lymphocyte (CTL) response and inhibit 
the growth of PDAC; (b) ADC measurement 
can offer an imaging biomarker for evaluation 
of therapeutic response of DC vaccination in 
PDAC.
Materials and methods
Our study was approved by the Institutional 
Animal Care and Use Committee (IACUC) of 
Northwestern University.
Cell lines and culture
The mouse Panc02 cell line is derived from 
amethylcholanthrene-induced pancreatic duc-
tal adenocarcinoma in C57BL/6 mice and was 
purchased from the American Type Culture 
Collection (ATCC; Rockville, MD). Panc02 cells 
were cultured in RPMI 1640 medium (Life 
Technologies, Carlsbad, CA) supplemented with 
glutamine (2 mmol/l, Life Technologies), pyru-
vate (1 mmol/l, Sigma-Aldrich, St. Louis, Mo), 
penicillin and streptomycin (100 IU/ml, Sigma-
Aldrich), and 10% fetal bovine serum (FBS, 
Sigma-Aldrich). The cells were maintained in a 
humidified atmosphere of 5% CO2 at 37°C. 
Before implantation, cell viability was assessed 
using trypan blue (Sigma-Aldrich) staining (cell 
viability of > 90% was confirmed prior to tumor 
implantation). 
UV-B irradiation of Panc02 cells
Panc02 cells were diluted in phosphate-buff-
ered saline (PBS) at a final concentration of 2 × 
106/ml, and were placed in a 6-well plate at 0.5 
ml per well. Panc02 cells were irradiated using 
UV-B light with 0.75 J/cm2. After irradiation, 
cells were maintained in culture medium. 12 h 
later, Panc02 cell apoptosis was confirmed by 
flow cytometric analysis using Annexin V/PI 
staining (Figure 1). The inactivated Panc02 
cells were collected for co-incubation with DCs.
Generation and antigen loading of bone 
marrow-derived DCs
The mouse bone marrow-derived DCs (BMDCs) 
were prepared as described in a previous publi-
cation with some modifications [28]. Briefly, 
female C57BL/6 mice (5-6 weeks of age, 
weighted between 16 and 19 g; Charles River, 
Wilmington, MA) were sacrificed by CO2 narco-
sis and cervical dislocation, and the tibias and 
femurs were harvested. After immersion in 70% 
ethanol for 5 mins, the bones were carefully 
dissected, and each half was flushed with FBS-
free RMPI 1640 (Gibco, Waltham, MA) in a cell 
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culture hood. The bone marrow cells were col-
lected, and erythrocytes were lysed with ammo-
nium chloride buffer (BD Biosciences, San 
Jose, CA). A total of 2 × 106 cells was cultured in 
10 mL RPMI supplemented with 10% FBS 
(Gibco, Waltham, MA), 100 units/mL penicillin, 
100 µg/mL streptomycin, 0.25 µg/mL ampho-
tericin b (antibiotic-antimycotic 100 ×, Gibco, 
Waltham, MA), 10 ng/mL rm-GM-CSF, and 1 
ng/mL rm-IL-4 (both from Shenandoah Bio- 
technology, Warwick, PA). Equal volume of the 
same culture media was added after 48 h. At 
day 7, lipopolysaccharide (LPS, 250 ng/ml) and 
interferon γ (IFNγ, 100 ng/ml) were added for 
24 h. Loosely adherent cells were then harvest-
ed, and the expression of DC markers was ana-
lyzed by fluorescence-activated cell sorting 
(FACS) as described below. BMDCs were co-
incubated with the inactivated Panc02 cells at 
a DC/Panc02 cell ratio of 10:1 for 24 hours. At 
day 9, loosely adherent cells (Panc02-pulsed 
DCs) were harvested, washed and resuspend-
ed in PBS, and analyzed by FACS.
FACS
Pan02-pulsed DCs were collected after 8 d of 
in vitro culture and washed with cold PBS. 
BMDC were stained by incubation for 40 mins 
at 4°C with 2 µg/3 × 105 cells anti-mouse 
PerCP-CyTM5.5 CD11c monoclonal antibody 
(mAb), PerCP-CyTM5.5 CD11b mAb, PE CD80 
mAb, APC CD86 mAb, PE H2Db mAb, FITC H2Kb 
mAb (all from BD Bioscience, San Jose, CA), PE 
MHC class II mAb (Southern Biotech, Birming- 
ham, AL), and appropriate isotype controls. The 
expression of DC markers was quantified by 
fluorescence-activated cell sorting (FACS) us- 
ing flow cytometry (BD LSRFortessaTM cell ana-
lyzer, San Jose, CA) and analyzed using FlowJo 
(Ashland, OR). 
Migration of Panc02-pulsed DCs to spleens via 
IP injection
Migration of Panc02-pulsed DCs to spleens 
after IP injection was visualized, as spleen is 
the largest lymphoid organ in the abdominal 
cavity. 1 × 107 Panc02-pulsed DCs in 100 µL 
Diluent C were mixed with 0.4 µL PKH26 dye in 
equal volume of Diluent C for 5 mins (Sigma-
Aldrich, St. Louis, MO). After adding 200 µL FBS 
and washing 3 times with PBS, the DCs were 
labeled with PKH26. Twelve C57BL/6 mice 
were IP injected with 1 × 107 PKH26-labeled 
Panc02-pulsed DCs in 100 µL PBS. 6 mice 
were randomly euthanized at each time point (6 
h and 12 h after IP injection) to harvest the 
spleens for fluorescence staining. The collect-
ed spleen tissues were embedded in OCT 
(Fisher HealthCare, Houston, TX) infused 
modes that were placed on dry ice and frozen 
at -80°C after 2 mins. The frozen samples were 
cut into 5 µm thick slices with the microtome 
and placed on slides. Then the slides were 
mounted by cover glasses with ProLong Glod 
Antifade Reagent with DAPI (Cell Signaling 
Technology, Danvers, MA) and visualized by 
fluorescent microscope (Axioimager Z1, Carl 
Zeiss, Ontario, CA). Three representative fluo-
rescent microscopy images were acquired from 
each sample with the same filter settings at the 
same magnifications. Total cells counts and 
PKH26 positive cells counts from the fluores-
cence microscopy images were quantified 
using ImageJ software (NIH, Bethesda, MD). 
The ratio of PKH26 positive cells to total num-
ber of cells was calculated for each sample.
Orthotopic mouse model of pancreatic cancer 
Female C57BL/6 mice were used for establish-
ing orthotopic pancreatic cancer models. The 
orthotopic mouse model of pancreatic cancer 
was prepared using previously published proto-
cols with modifications [29]. 1 × 105 viable 
Panc02 cells were gently mixed with ice-cold 
Figure 1. Apoptosis in Panc02 cells after UV-B irra-
diation. 12 hours after UV-B irradiation, apoptosis in 
Panc02 cells was assessed by flow cytometric analy-
sis using Annexin V/PI staining. The inactivation of 
all Panc02 cells was confirmed before co-incubation 
with DCs.
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Matrigel (Sigma-Aldrich) at a ratio of 3:1 to pro-
duce a homogeneous suspension. Anesthesia 
was induced and maintained in each mouse by 
inhalation of 2% isoflurane in oxygen at a rate 
of 1 L/min (Isoflurane Vaporizer, Vaporizer 
Sales and Services, Rockmart, GA). After local 
shaving and disinfection, the abdominal cavity 
was opened by a 1.5-cm longitudinal incision at 
the left upper quadrant. The tail of the pancre-
as was identified by mobilization of the spleen. 
5 μL of Panc02 cell-Matrigel suspension was 
then slowly injected into the parenchyma of 
pancreatic tail. To prevent further leakage, the 
needle was kept in the injection site for 30 s 
prior to removal. The spleen and pancreas were 
placed back into the abdominal cavity, and the 
abdominal cavity was closed by a running two-
layer silk suture. Postoperative status and 
wound healing were monitored every day for 
one week. After one week, a visible nodule at 
the location of pancreatic tail was detected by 
magnetic resonance imaging (MRI) in all eigh-
teen mice (protocols described below), which 
indicated that the orthotopic pancreatic cancer 
models were established successfully.
Therapeutic strategy
Twelve mice with orthotopic pancreatic cancer 
were randomly divided into two groups: treat-
ment group (n = 6) and control group (n = 6). 
Therapeutic strategy was started one week 
after tumor implantation. The mice in the treat-
ment group underwent IP injection of 1 × 107 
Panc02-pulsed DCs in 100 μL PBS for thera-
peutic vaccination, and the mice in the control 
group underwent IP injection of 100 μL saline 
solution. IP injection was administered once a 
week for 5 weeks.
CTL assay
Twelve orthotopic pancreatic cancer mice and 
six age-matched normal C57BL/6 mice were 
used for CTL assay. One week after tumor 
implantation, six of the mice with orthotopic 
pancreatic cancer were IP injected with 1 × 107 
Panc02-pulsed DCs in 100 μL PBS, and the 
other six were IP injected with 1 × 107 unpulsed 
mature DCs in 100 μL PBS. IP injection was 
administered once a week for 3 weeks. The six 
normal C57BL/6 mice that did not undergo any 
operation were used as another control group. 
After sacrifice, spleens were harvested and 
homogenized to release splenocytes in RPMI 
1640 medium. The single-cell suspension was 
prepared, and CD8+ T cells were isolated using 
magnetic cell sorting by negative selection 
(CD8a+ T cell isolation Kit, Miltenyi Biotec) 
according to the manufacturer’s instructions. 
Panc02-pulsed DC-induced, unpulsed DC-in- 
duced, and normal murine CD8+ T cells were 
prepared. Flow cytometry confirmed > 95% 
purity. Lactate dehydrogenase (LDH) assay was 
performed to determine the cytotoxicity of the 
purified CD8+ T cells using Cytotoxicity De- 
tection KitPLUS (Sigma-Aldrich). For LDH assay, 
Panc02 cells (target cells) were collected and 
plated at 3000 cells/well in a flat-bottom 
96-well cell culture plate (BD Biosciences, San 
Diego, CA, USA). Then, CD8+ T cells (effector 
cells) were added to the 96-well plates at differ-
ent effector-to-target (E:T) ratios (5:1, 10:1, 
20:1 and 40:1), and 2% Triton X-100 lysing solu-
tion was added to the wells that were prepared 
for maximal LDH release measurement. The 
plate was incubated at 37°C for 4 h. After incu-
bation, the plates were centrifuged for 10 min 
at 330 × g, and 100 μL/well cell-free superna-
tant was transferred into the corresponding 
wells of an optically clear, flat-bottom 96-well 
plate. Then, 100 μL mixed detection kit reagent 
was added to each well, and cells were incu-
bated at room temperature in the dark for 30 
min. After incubation, the absorbance was 
measured using a multiwell plate reader at 490 
nm. The percentage of cytotoxicity was calcu-
lated according to the following equation: cyto-
toxicity (%) = [(ET - E) - T]/(Max - T) × 100, where 
ET is the LDH release by effector-target reac-
tion, E is the spontaneous LDH release of effec-
tor cells, T is the spontaneous LDH release of 
target cells, and Max is the maximal LDH 
release from complete target cell lysis.
MRI examination
MRI examinations were performed by using a 
7.0 T small-animal MRI scanner with a commer-
cial mouse coil (ClinScan, Bruker Biospin). One 
week after tumor implantation, all the mice 
underwent MRI examination to confirm the suc-
cessful establishment of orthotopic pancreatic 
cancer models. The mice in the treatment 
group and the control group underwent MRI 
examination at one week, three weeks, and five 
weeks after initiation of treatment for monitor-
ing tumor growth and evaluating the response 
to therapies in vivo. Mice were anesthetized by 
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inhalation of a mixture of 2% isoflurane and 
oxygen at 1 L/min, and body temperature was 
monitored continuously and was controll- 
ed with a water bed (SA Instruments, Stony 
Brook, NY). The MRI sequences and parame-
ters were as follows: (a) axial T1-weighted imag-
ing (T1WI): repetition time (TR)/echo time (TE) = 
630/20 ms; field of view (FOV) = 27 mm × 
30 mm; matrix size = 134 × 192; slice thick-
ness (ST) = 0.8 mm; gap = 0 mm; (b) axial 
T2-weighted imaging (T2WI): TR/TE = 1581/ 
40 ms; FOV = 21 mm × 30 mm; matrix size = 
180 × 256; ST = 0.8 mm; gap = 0 mm; (c) coro-
nal T2WI: TR/TE = 2500/40 ms; FOV = 23 
mm × 32 mm; matrix size = 142 × 192; ST = 
0.8 mm; gap = 0 mm; (d) sagittal T2-weighted 
imaging: TR/TE = 2500/40 ms; FOV = 24 mm × 
30 mm; matrix size = 154 × 192; ST = 0.5 mm; 
gap = 0 mm; (e) axial diffusion-weighted im- 
aging (DWI): TR/TE = 3500/40 ms; FOV = 28 
mm × 28 mm; matrix size = 82 × 82; ST = 1 
mm; gap = 0 mm; b-value = 0 and 800 s/mm2. 
DWI was performed in 3 orthogonal directions 
of the diffusion gradients.
MR image analysis
MR images were analyzed by a radiologist with 
more than 5 years of experience. In vivo tumor 
size measurement was performed by using an 
open source software ITK-SNAP (version 3.6.0, 
University of Pennsylvania) by measuring both 
the longest diameter and tumor volume. The 
longest diameter of each orthotopic tumor was 
measured on either axial, coronal or sagittal 
T2-weighted images. For tumor volume mea-
surement, free-hand regions of interest (ROIs) 
were traced along the tumor margin on each 
slice of axial T2-weighted images containing a 
orthotopic tumor, and then the three-dimen-
sional volume was calculated [30]. The change 
in the longest diameter (Δdiameter) after five 
weeks of treatment was calculated according 
to the equation: Δdiameter = diameter5w - diam-
eter1w, where diameter1w and diameter5w are 
the longest diameters that measured at one 
week and five weeks after initiation of treat-
ment, respectively. The change in tumor vol-
ume (Δvolume) after five weeks of treatment 
was calculated according to the equation: 
Δvolume = volume5w - volume1w, where volume1w 
and volume5w are the tumor volumes that mea-
sured at one week and five weeks after initia-
tion of treatment, respectively.
Diffusion-weighted images were postproce- 
ssed to generate ADC maps in Matlab R2016b 
(Mathworks, Natick, MA). Using axial T2-weight- 
ed images as reference, a free-hand ROI was 
drawn inside the tumor on the slice of ADC 
maps with the largest tumor area, avoiding 
regions with necrosis and artifacts, and the 
mean ADC for each orthotopic tumor was 
recorded. The change in tumor ADC (ΔADC) 
after five weeks of treatment was calculated 
according to the equation: ΔADC = ADC5w - 
ADC1w, where ADC1w and ADC5w are, respective-
ly, the tumor ADC that measured at one week 
and five weeks after initiation of treatment.
Statistical analysis
Statistical analysis was performed using SPSS 
(version 22.0; SPSS, Chicago, IL). The results 
are presented as mean ± standard deviation 
(SD). Mann-Whitney U test was applied to com-
pare the difference between the ratio of PKH26 
positive DCs to the total cells in the spleens 
harvested 6 h and 12 h after IP injection. 
Repeated measures ANOVA analysis was 
applied to compare the differences in the lon-
gest diameter and tumor volume between the 
treatment and the control group and the ch- 
anges over time. Student’s t test was used to 
compare the differences in ΔADC and Δvolu- 
me between the treatment group and the con-
trol group. The differences in the cytotoxicity 
between normal, MDI, and PDI CD8+ T cells 
were determined using One-Way ANOVA analy-
sis followed by LSD test for multiple compari-
sons. Pearson correlation coefficient (r) and 
95% confidence interval (CI) was calculated to 
assess the relationship between Δdiameter 
and ΔADC, and the relationship between 
Δvolume and ΔADC. For the absolute value of r, 
0-0.19 is regarded as very weak, 0.2-0.39 as 
weak, 0.40-0.59 as moderate, 0.6-0.79 as 
strong, and 0.8-1.0 as very strong correlation. P 
< 0.05 was considered to indicate a significant 
difference in all statistical tests.
Results
Purity and maturity of bone marrow-derived 
DCs and Panc02-pulsed DCs
The purities of DCs in BMDCs were analyzed on 
FACS by assessing the population of cells with 
positive CD11b and CD11c expression. As 
shown in Figure 2, the population of DCs in 
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Figure 2. The immunophenotypes of bone marrow-derived cells in vitro culture for 8 days and Panc02-pulsed DCs. A. The immunophenotypes of bone marrow-
derived cells in vitro culture for 8 days. B. The immunophenotypes of Panc02-pulsed DCs. The results showed that the purity of CD11b+ DCs and CD11c+ DCs were 
more than 75% for both bone marrow-derived cells 8 days after in vitro culture and Panc02-pulsed DCs. The high expression of the maturation surface markers 
CD80, CD86, H2Db, H2Kb and MHC class II indicated that the DCs were in a mature state.
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BMDCs that being cultured in vitro for 8 days 
(Figure 2A) and in BMDCs that being pulsed by 
Panc02 cells (Figure 2B) both achieved higher 
than 75%. The maturation of DCs was evaluat-
ed by measuring the expression level of matu-
ration surface markers CD80, CD86, H2Db, 
H2Kb, and MHC class II, indicating that the DCs 
after in vitro culture were in a mature state that 
ready to present antigen to T cells (Figure 2).
Migration of fluorescence-labeled Panc02-
pulsed DCs to spleens via IP injection
In order to track the migration of Panc02-
pulsed DCs to spleen, the levels of PKH26-
labeled DCs in the spleen were detected by flu-
orescence microscopy. For spleens harvested 
6 h and 12 h after IP injection, the mean ratios 
of PKH26 positive DCs to the total number of 
cells were (1.24 ± 0.12) × 10-2 and (2.52 ± 
0.26) × 10-2, respectively (Figure 3A and 3B). 
The ratio of positive DCs in spleens harvested 
12 h after IP injection was significantly higher 
than that harvested 6 h after IP injection (P = 
0.002, Figure 3C), indicating the accumulative 
migration of Panc02-pulsed DCs in spleens.
CTL responses induced by IP injection of 
Panc02-pulsed DCs
To study the anti-tumor toxicity of CTLs that 
stimulated by Panc02-pulsed DCs, the CD8+ T 
cells are purified after IP injection of Panc02-
pulsed DCs, and its cytotoxicity was evaluat- 
ed by measuring the LDH that released by 
co-cultured Panc02 cells. Normal murine CD8+ 
T cells were used as controls. IP injection of 
Panc02-pulsed DCs induced a significantly 
higher level of CTL response against Panc02 
cells compared to IP injection of unpulsed DCs 
or normal murine CD8+ T cells (Figure 4). 
Figure 3. The migration of Panc02-pulsed DCs to spleens after IP injection. A. The representative fluorescent micros-
copy image of spleen harvested 6 h after IP injection (scale bar: 50 μm). B. The representative fluorescent micros-
copy image of spleen harvested 12 h after IP injection (scale bar: 50 μm). The PKH26-labeled Panc02-pulsed DCs 
(red) were detected in spleen tissues (splenic cells, blue). C. A box plot of the ratio of PKH26 positive DCs amount 
to the total number of cells for spleens harvested 6 h and 12 h after IP injection. The box plot displays the full range 
of variation (from min to max), and dots indicate individual values. The positive DCs ratio for spleens harvested 12 
h after IP injection was significantly higher than the ratio for spleens harvested 6 h after IP injection (P = 0.002).
Figure 4. Cytotoxicity of Panc02-pulsed DC-induced, 
unpulsed DC-induced and normal murine CD8+ T 
cells against Panc02 cells. After three times of IP in-
jection, the CTL response was determined by evalu-
ating the splenic CD8+ T-cell cytotoxicity using LDH 
assay. Normal murine CD8+ T cells were used as 
controls. IP injection of Panc02-pulsed DCs induced 
significantly a higher level of CTL response against 
Panc02 cells compared to IP injection of unpulsed 
DCs (E:T = 40:1, 30.80 ± 2.71% specific lysis in 
Panc02-pulsed DC-induced T cell/Panc02 group vs 
16.74 ± 2.46% specific lysis in unpulsed DC-induced 
T cell/Panc02 group, or 7.28 ± 1.57% specific lysis 
in normal murine T cell/Panc02 group, P < 0.0001).
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Therefore, the Panc02-pulsed DCs are capable 
to trigger strong anti-tumor immunity of CD8+ T 
cells. 
In vivo tumor size measurement on MR images
Representative axial T2-weighted images of the 
pancreatic tumors in the treatment group and 
control group at different therapeutic time 
points were shown in Figure 5A-F. At one 
week, three weeks, and five weeks after initia-
tion of treatment, the mean longest diameters 
were 2.29 ± 0.50 mm, 5.04 ± 1.06 mm, and 
8.83 ± 0.97 mm for the treatment group and 
3.04 ± 0.87 mm, 6.10 ± 0.48 mm, and 10.93 ± 
1.62 mm for the control group respectively 
(Figure 5G). The mean Δdiameters were 6.21 ± 
1.42 mm for the treatment group and 7.89 ± 
2.05 mm for the control group. There were 
no significant differences in the longest diame-
ters between the treatment and the control 
group at one week (P = 0.097) and three weeks 
after initiation of treatment (P = 0.500). The 
longest diameter in the control group was sig-
nificantly longer than that in the treatment 
group at five weeks after initiation of treatment 
(P = 0.021). However, there was no significant 
difference in Δdiameter between the treatment 
Figure 5. In vivo tumor size measurement on T2-weighted images. (A-C) Representative axial T2-weighted images 
of one pancreatic tumor (dash line) in the control group at one week (A), three weeks (B) and five weeks (C) after 
initiation of treatment. (D-F) Representative axial T2-weighted images of one pancreatic tumor (dash line) in the 
treatment group at one week (D), three weeks (E) and five weeks (F) after initiation of treatment. (G) Changes of 
tumor longest diameters for the treatment and control group at different therapeutic time points (error bars indicate 
SD). There were no significant differences in the longest diameters of the pancreatic tumors between the treatment 
and the control group one week (P = 0.097) and three weeks after initiation of treatment (P = 0.500). The longest 
diameters of the pancreatic tumors in the control group were significantly longer than those in the treatment group 
five weeks after initiation of treatment (P = 0.021). (H) Changes of tumor volumes in the treatment and the control 
group at different therapeutic time points (error bars indicate SD, *P < 0.05). There were no significant differences 
in tumor volumes between the treatment and the control group one week after initiation of treatment (P = 0.076). 
Tumor volumes in the control group were significantly larger than those in the treatment group three weeks (P = 
0.004) and five weeks after initiation of treatment (P = 0.001).
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group and the control group (P = 0.129). On 
the other hand, the tumor volumes have ex- 
perienced a more dynamic change. The mean 
tumor volumes were 4.64 ± 1.50 mm3, 25.75 ± 
10.64 mm3, and 110.23 ± 24.30 mm3 for 
the treatment group and 10.08 ± 6.58 mm3, 
54.42 ± 16.02 mm3, and 209.89 ± 48.69 
mm3 for the control group (Figure 5H). The 
mean Δvolumes were 105.59 ± 23.31 mm3 
for the treatment group and 211 ± 45.42 mm3 
for the control group. There was no signifi- 
cant difference in tumor volume between 
the treatment and the control group at one 
week after initiation of treatment (P = 0.076). 
Tumor volume in the control group was signifi-
cantly higher than that in the treatment gro- 
up at three weeks (P = 0.004) and five weeks 
after initiation of treatment (P = 0.001). Also, 
Δvolume in the treatment group was significant-
ly smaller than that in the control group (P < 
0.0001).
ADC measurement
Representative axial ADC maps of pancreatic 
tumors in the treatment group and control 
group at different therapeutic time points were 
shown in Figure 6A-F. The mean ΔADCs were 
(-0.14 ± 0.13) × 10-4 mm2/s for the treatment 
group and (-0.54 ± 0.22) × 10-4 mm2/s for the 
control group. ΔADC in the treatment gro- 
up was significantly higher than that in the 
control group (P = 0.004, Figure 6G). There was 
no significant correlation between ΔADC and 
Δdiameter (r = -0.440, 95% CI, -0.848 to 0.509, 
P = 0.152, Figure 6H), but a very strong nega-
tive correlation between ΔADC and Δvolume (r 
= -0.882, 95% CI, -0.967 to -0.701, P < 0.0001, 
Figure 6I).
Figure 6. ADC measurement on ADC maps of DW-MRI. (A-C) Representative axial ADC maps of one pancreatic tumor 
(dash line) in the control group at one week (A), three weeks (B) and five weeks (C) after initiation of treatment. (D-F) 
Representative axial ADC maps of one pancreatic tumor (dash line) in the treatment group at one week (D), three 
weeks (E) and five weeks (F) after initiation of treatment. (G) A box plot of ΔADC for the treatment and control group 
(error bars indicate SD, and dots indicate individual values). ΔADC of the pancreatic tumor in the treatment group 
was significantly higher than that in the control group (P = 0.004). (H) A scatter plot of the correlation between the 
change in the longest diameter (Δdiameter) and the change in ADC (ΔADC) after five weeks of treatment. There was 
no significant correlation between ΔADC and Δdiameter (r = -0.440, 95% CI, -0.848 to 0.509, P = 0.152). (I) A scat-
ter plot of the correlation between the change in tumor volume (Δvolume) and the change in ADC (ΔADC) after five 
weeks of treatment. There was a very strong negative correlation between ΔADC and Δvolume (r = -0.882, 95% CI, 
-0.967 to -0.701, P < 0.0001).
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Discussion
This study provided an effective DC vaccination 
in a murine PDAC model and successfully moni-
tored the tumor response using ADC measure-
ment. Firstly, our results demonstrated that 
Panc02-pulsed DC vaccination administered 
via IP injection induces a tumor-specific CTL 
response and inhibits tumor growth in a murine 
PDAC model. Following five weeks of DC vacci-
nation, there was a significant difference in the 
reduction of tumor ADC between the treatment 
group and the control group; furthermore, a 
strong correlation was observed between the 
change in tumor ADC and the change in tumor 
volume.
In this study, the Panc02 murine orthotopic 
pancreatic tumor model was used, which is the 
animal model mimics both histologic character-
istics and biological behaviors of human PDAC, 
and is ideal for testing the efficacy of DC vacci-
nation in the treatment of PDAC [28, 31, 32]. In 
this study, apoptotic Panc02 cells generated by 
UV-B irradiation was used for DC vaccine prepa-
ration due to its advantage in antigen loading 
effectiveness and the capacity of loaded DC in 
T-cells activation [33]. Our results showed that 
there was a significant increase in the level of 
CTL response induced by Panc02-pulsed DCs 
compared with that induced by unpulsed DCs. 
As for the administration route of DC vaccine, 
previous studies have shown that DCs failed to 
migrate into secondary lymphoid tissues after 
intratumoral injection, resulting in an inferior 
capacity to induce adaptive immunity [19, 34]. 
Lesterhuis et al [18] found that the more labori-
ous and variable intranodal route did not offer 
an advantage over intradermal route. Although 
intradermal and subcutaneous injection are 
the most common routes for vaccination in 
human clinical trials, low migration rate is the 
major obstacle that leads to low efficacy [35]. 
IP injection of DC vaccine in this study is easy to 
apply, and could deliver a relatively large vol-
ume of DC vaccine can be injected at multiple 
time points. The migration of Panc02-pulsed 
DCs to the spleen and LNs after IP injection 
was tested, and a large amount of labeled 
Panc02-pulsed DCs were observed in those 
lymphoid organs 12 h after IP injection. Our 
results indicated that IP injection of DC vaccine 
could be a potential regimen for pancreatic 
cancer. 
In most mouse PDAC therapeutic studies, 
tumor size was conventionally assessed by 
standard dissection techniques with the manu-
al caliper measurements, which could only pro-
vide the endpoint data. Compared with the con-
ventional assessment method, MRI could 
provide noninvasive longitudinal in vivo mea-
surements of tumor growth with higher accura-
cy and repeatability. Besides, the evaluation of 
cancer therapeutics is conventionally based on 
measurements of the longest tumor diameters 
in clinical settings, which are adopted by the 
revised Response Evaluation Criteria in Solid 
Tumors guideline (RECIST, version 1.1) [36]. 
Volume-based size measurements are more 
effective than one-dimensional or two-dimen-
sional measurements in clinical settings, and 
the change in tumor volume could be used to 
predict the overall survival and recurrence-free 
survival of patients in clinical trials [37]. Ac- 
cording to our results, the tumor volume was 
more sensitive in detecting the changes of 
tumor size compared to the longest diamet- 
er. The results of this study indicated that the 
measurement of tumor volume could better 
reflect therapeutic response of DC vaccination 
in PDAC than that of the longest diameter. 
Zhang et al [38] showed that quantitative ADC 
measurement reflected pancreatic tumor mi- 
crostructure in a rat model. In this study, the 
value of ADC measurement in monitoring thera-
peutic response of DC vaccination in PDAC was 
investigated. The results showed that the 
reduction of tumor ADC in the treatment group 
was less than that in the control group. 
Moreover, the change in tumor ADC was corre-
lated negatively with the change in tumor vol-
ume after five weeks of treatment; however, 
there was no significant correlation between 
the change in tumor ADC and the change in the 
longest diameter. These results indicated that 
ADC measurement could provide a valuable 
imaging biomarker of therapeutic response to 
DC vaccination in pancreatic cancer. 
The current study had several limitations. First, 
the sample size of mice pancreatic tumor 
model was small, and we will enlarge the sam-
ple size in the future. Second, MRI examina-
tions were performed at only three time points 
after initiation of treatment; further investiga-
tions will include more time points as well as 
the over survival rate. Third, we also found that 
programmed cell death receptor ligand 1 (PD-
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L1) was highly expressed in the murine pancre-
atic tumor model, which was considered to be 
involved in the mechanism of downregulating 
the antitumor response [39]. However, we did 
not explore it in depth in this study. DC vaccina-
tion combining with immune checkpoint inhibi-
tors, such as PD-1/PD-L1-inhibitors, is the 
future direction of our work.
In conclusion, this study demonstrated the effi-
cacy of DC vaccination administered via IP 
injection for immunotherapy in murine PDAC 
model, and the feasibility of ADC measurement 
as an imaging biomarker for assessment of 
therapeutic responses in immunotherapy.
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